JFJingru Fang

Jingru Fang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jingru Fang has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RNA folding drives species-dependent host mRNA partitioning in Ebola virus condensates

    by Jingru Fang, Dylan C. Lam, Clarence K. Mah, Reika Watanabe, Hailey M. Tanner, Troy Comi, Yuan Cai, Cheng-Yi Chen, Aartjan J. W. Te Velthuis, Clifford P. Brangwynne, et al.

    Summary: RNA viruses form membraneless condensates in host cells to drive replication, but whether these compartments regulate host RNAs remains unclear. Using MERFISH-based subcellular transcriptomics, we quantified cellular mRNA recruitment into Ebola virus condensates under basal and IFN-stimulated states. We find in the basal state, cellular RNAs with minimally folded coding regions are selectively recruited. Under IFN-stimulation, however, interferon-stimulated genes (ISGs) with structured 3′UTRs concentrate in viral condensates. We find both RNA structural features are conserved in the viral genome and support its retention in condensates. In parallel, for cellular mRNAs, we find partitioning into condensates prolongs RNA half-life and amplifies, rather than dampening, ISG expression. Fruit bats, which do not experience severe disease from RNA viruses, instead have ISGs with reduced 3′UTR folding, and may evade condensate-sequestration, enabling balanced antiviral responses. This selective stabilization links condensate function to RNA regulation as a molecular determinant of viral-host co-evolution and disease pathogenesis. In Brief: Viral condensates are increasingly recognized as hubs for viral replication, but how they interact with host RNAs is poorly understood. This study reveals that Ebola virus condensates selectively recruit and stabilize host mRNAs, reshaping antiviral gene expression in ways that differ between humans and bats.

  • Open Access

    Spatial and functional arrangement of Ebola virus polymerase inside phase-separated viral factories

    by Jingru Fang, Guillaume Castillon, Sebastien Phan, Sara McArdle, Chitra Hariharan, Aiyana Adams, Mark H. Ellisman, Ashok A. Deniz, Erica Ollmann Saphire

    Ebola virus (EBOV) infection induces the formation of membrane-less, cytoplasmic compartments termed viral factories, in which multiple viral proteins gather and coordinate viral transcription, replication, and assembly. Key to viral factory function is the recruitment of EBOV polymerase, a multifunctional machine that mediates transcription and replication of the viral RNA genome. We show that intracellularly reconstituted EBOV viral factories are biomolecular condensates, with composition-dependent internal exchange dynamics that likely facilitates viral replication. Within the viral factory, we found the EBOV polymerase clusters into foci. The distance between these foci increases when viral replication is enabled. In addition to the typical droplet-like viral factories, we report the formation of network-like viral factories during EBOV infection. Unlike droplet-like viral factories, network-like factories are inactive for EBOV nucleocapsid assembly. This unique view of EBOV propagation suggests a form-to-function relationship that describes how physical properties and internal structures of biomolecular condensates influence viral biogenesis.


  • Open Access

    Spatial and functional arrangement of Ebola virus polymerase inside phase-separated viral factories

    by Jingru Fang, Guillaume Castillon, Sebastien Phan, Sara McArdle, Chitra Hariharan, Aiyana Adams, Mark H. Ellisman, Ashok A. Deniz, Erica Ollmann Saphire

    Ebola virus (EBOV) infection induces the formation of membrane-less, cytoplasmic compartments termed viral factories, in which multiple viral proteins gather and coordinate viral transcription, replication and assembly. Key to viral factory function is the recruitment of EBOV polymerase, a multifunctional machine that mediates transcription and replication of the viral RNA genome. We show that intracellularly reconstituted EBOV viral factories are biomolecular condensates, with composition-dependent internal exchange dynamics that likely facilitates viral replication. Within the viral factory, we found the EBOV polymerase clusters into foci. The distance between these foci increases when viral replication is enabled. In addition to the typical droplet-like viral factories, we report the formation of network-like viral factories during EBOV infection. Unlike droplet-like viral factories, network-like factories are inactive for EBOV nucleocapsid assembly. This unique view of EBOV propagation suggests a form-to-function relationship that describes how physical properties and internal structures of biomolecular condensates influence viral biogenesis.

  • A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus

    by Haoyang Li, Tierra Buck, Michelle Zandonatti, Jieyun Yin, Alex Moon-Walker, Jingru Fang, Anatoliy Koval, Megan L. Heinrich, Megan M. Rowland, Ruben Diaz Avalos, et al.

    Developing potent therapeutics and effective vaccines are the ultimate goals in controlling infectious diseases. Lassa virus (LASV), the causative pathogen of Lassa fever (LF), infects hundreds of thousands annually, but effective antivirals or vaccines against LASV infection are still lacking. Furthermore, neutralizing antibodies against LASV are rare. Here, we describe biochemical analyses and high-resolution cryo-electron microscopy structures of a therapeutic cocktail of three broadly protective antibodies that target the LASV glycoprotein complex (GPC), previously identified from survivors of multiple LASV infections. Structural and mechanistic analyses reveal compatible neutralizing epitopes and complementary neutralization mechanisms that offer high potency, broad range, and resistance to escape. These antibodies either circumvent or exploit specific glycans comprising the extensive glycan shield of GPC. Further, they require mammalian glycosylation, native GPC cleavage, and proper GPC trimerization. These findings guided engineering of a next-generation GPC antigen suitable for future neutralizing antibody and vaccine discovery. Together, these results explain protective mechanisms of rare, broad, and potent antibodies and identify a strategy for the rational design of therapeutic modalities against LF and related infectious diseases.


  • Open Access

    Proximity interactome analysis of Lassa polymerase reveals eRF3a/GSPT1 as a druggable target for host-directed antivirals

    by Jingru Fang, Colette Pietzsch, Haydar Witwit, George Tsaprailis, Gogce Crynen, Kelvin Frank Cho, Alice Y. Ting, Alexander Bukreyev, Erica Ollmann Saphire, Juan Carlos de la Torre

    Completion of the Lassa virus (LASV) life cycle critically depends on the activities of the virally encoded, RNA-dependent RNA polymerase in replication and transcription of the viral RNA genome in the cytoplasm of infected cells. The contribution of cellular proteins to these processes remains unclear. Here, we applied proximity proteomics to define the interactome of LASV polymerase in cells under conditions that recreate LASV RNA synthesis. We engineered a LASV polymerase-biotin ligase (TurboID) fusion protein that retained polymerase activity and successfully biotinylated the proximal proteome, which allowed the identification of 42 high-confidence LASV polymerase interactors. We subsequently performed a small interfering RNA (siRNA) screen to identify those interactors that have functional roles in authentic LASV infection. As proof of principle, we characterized eukaryotic peptide chain release factor subunit 3a (eRF3a/GSPT1), which we found to be a proviral factor that physically associates with LASV polymerase. Targeted degradation of GSPT1 by a small-molecule drug candidate, CC-90009, resulted in strong inhibition of LASV infection in cultured cells. Our work demonstrates the feasibility of using proximity proteomics to illuminate and characterize yet-to-be-defined host-pathogen interactome, which can reveal new biology and uncover novel targets for the development of antivirals against highly pathogenic RNA viruses.


  • Open Access

    Functional interactomes of the Ebola virus polymerase identified by proximity proteomics in the context of viral replication

    by Jingru Fang, Colette Pietzsch, George Tsaprailis, Gogce Crynen, Kelvin Frank Cho, Alice Y. Ting, Alexander Bukreyev, Juan Carlos de la Torre, Erica Ollmann Saphire


  • Open Access

    Functional interactomes of the Ebola virus polymerase identified by proximity proteomics in the context of viral replication

    by Jingru Fang, Colette Pietzsch, George Tsaprailis, Gogce Crynen, Kelvin Frank Cho, Alice Y. Ting, Alexander Bukreyev, Juan Carlos de la Torre, Erica Ollmann Saphire

    SUMMARY: Ebola virus (EBOV) critically depends on the viral polymerase to replicate and transcribe the viral RNA genome in the cytoplasm of host cells, where cellular factors can antagonize or facilitate the virus life cycle. Here we leveraged proximity proteomics and conducted an siRNA screen to define the functional interactome of EBOV polymerase. As proof-of-principle, we validated two cellular mRNA decay factors from 35 identified host factors: eukaryotic peptide chain release factor subunit 3a (eRF3a/GSPT1) and up-frameshift protein 1 (UPF1). Our data suggest that EBOV can subvert restrictions of cellular mRNA decay and repurpose both GSPT1 and UPF1 to promote viral replication. Treating EBOV-infected human hepatocytes with a drug candidate that targets GSPT1 for degradation significantly reduced viral RNA load and particle production. Our work demonstrates the utility of proximity proteomics to capture the functional host-interactome of the EBOV polymerase and to illuminate host-dependent regulations of viral RNA synthesis.

  • Open Access

    Proximity interactome analysis of Lassa polymerase reveals eRF3a/GSPT1 as a druggable target for host directed antivirals

    by Jingru Fang, Colette Pietzsch, Haydar Witwit, George Tsaprailis, Gogce Crynen, Kelvin Frank Cho, Alice Y. Ting, Alexander Bukreyev, Erica Ollmann Saphire, Juan Carlos de la Torre

    Completion of the Lassa virus (LASV) life cycle critically depends on the activities of the virally encoded RNA-dependent RNA polymerase in replication and transcription of the negative-sense RNA viral genome in the cytoplasm of infected cells. We hypothesized that interactions with an array of cellular proteins may enable LASV polymerase to execute distinct viral RNA biosynthetic processes. To investigate this hypothesis, we applied proximity proteomics to define the interactome of LASV polymerase in cells, under conditions that recreate viral transcription and replication. We engineered a LASV polymerase-biotin ligase TurboID fusion protein that retained polymerase activity and successfully biotinylated the proximal proteome, which allowed us to identify 42 high-confidence hits that interact with LASV polymerase. We performed an siRNA screen to evaluate the role of the identified interactors in LASV infection, which uncovered six host factors for which their depletion affected LASV infection. We found that one polymerase interactor, eukaryotic peptide chain release factor subunit 3a (eRF3a/GSPT1), physically and functionally associated with LASV polymerase, exhibiting proviral activity. Accordingly, pharmacological targeting of GSPT1 resulted in strong inhibition of LASV infection. In summary, our work demonstrates the feasibility of using proximity proteomics to illuminate and characterize yet to be defined, host-pathogen interactomes, which can reveal new biology and uncover novel targets for the development of antivirals against LASV. Significance Statement Lassa virus (LASV), the causative agent of Lassa fever (LF), poses an important public health problem in Western Africa, and current therapeutic interventions are very limited. Due to its limited genome coding capacity, LASV proteins are often multifunctional and orchestrate complex interactions with cellular factors to execute the steps required to complete its viral life cycle. LASV polymerase is essential for the replication and expression of the viral genome, and it is consequently an attractive target for antiviral intervention. Here we present the first host interactome of LASV polymerase, which can guide the identification of novel druggable host cellular targets for the development of cost-effective antiviral therapies against LF.

  • Open Access

    Staufen1 Interacts with Multiple Components of the Ebola Virus Ribonucleoprotein and Enhances Viral RNA Synthesis

    by Jingru Fang, Colette Pietzsch, Palaniappan Ramanathan, Rodrigo I. Santos, Philipp A. Ilinykh, Mariano A. Garcia-Blanco, Alexander Bukreyev, Shelton S. Bradrick

    Ebola virus (EBOV) is a negative-strand RNA virus with significant public health importance. Currently, no therapeutics are available for Ebola, which imposes an urgent need for a better understanding of EBOV biology. Here we dissected the virus-host interplay between EBOV and host RNA-binding proteins. We identified novel EBOV host factors, including Staufen1, which interacts with multiple viral factors and is required for efficient viral RNA synthesis.


  • Open Access

    Aminopeptidase secreted by Chromobacterium sp. Panama inhibits dengue virus infection by degrading the E protein

    by Raúl G Saraiva, Jingru Fang, Seokyoung Kang, Yesseinia I Angleró-Rodríguez, Yuemei Dong, George Dimopoulos

    Dengue virus (DENV) is the most prevalent and burdensome arbovirus transmitted by Aedes mosquitoes, against which there is only a limited licensed vaccine and no approved drug treatment. A Chromobacterium species, C. sp. Panama, isolated from the midgut of A. aegypti is able to inhibit DENV replication within the mosquito and in vitro. Here we show that C. sp. Panama mediates its anti-DENV activity through secreted factors that are proteinous in nature. The inhibitory effect occurs prior to virus attachment to cells, and is attributed to a factor that destabilizes the virion by promoting the degradation of the viral envelope protein. Bioassay-guided fractionation, coupled with mass spectrometry, allowed for the identification of a C. sp. Panama-secreted neutral protease and an aminopeptidase that are co-expressed and appear to act synergistically to degrade the viral envelope (E) protein and thus prevent viral attachment and subsequent infection of cells. This is the first study characterizing the anti-DENV activity of a common soil and mosquito-associated bacterium, thereby contributing towards understanding how such bacteria may limit disease transmission, and providing new tools for dengue prevention and therapeutics. The global burden of dengue cannot be overstated, and lack of effective control measures, besides avoiding contact with the mosquito vector, creates an urgent need to develop new strategies to control the disease. Here we elucidate the mechanism by which a natural soil bacterium inhibits DENV infection. Chromobacterium sp. Panama secretes a protease that is able to undermine the integrity of the viral particles, preventing their attachment and thus infection of host cells. This study contributes towards understanding how natural bacteria of the vector gut may limit disease transmission, and provides new candidate tools for the development of dengue transmission-blocking and therapeutic agents.